legislative

CBD and Cannabis-Derived Products Issue Page

Cannabidiol (CBD) and Cannabis-Derived Products

CBD can be used to treat seizures and other symptoms. As CBD products become more popular, there are increasing questions about their safety, legality, and impacts on safety-sensitive industries, including chemical distribution. NACD supports the U.S. Food and Drug Administration in its efforts to study the long-term impacts of CBD use and encourages the agency to establish a regulatory framework for its safe and legal distribution.

Background

The hemp-derived chemical compound Cannabidiol (CBD) is found on the market today in food and drug products that are not yet regulated by the U.S. Food and Drug Administration (FDA) except in the prescription drug Epidiolex, a medicine intended to treat pediatric patients suffering from seizures caused by Lennox-Gastaut syndrome or Dravet syndrome.[1] CBD products, unlawfully on the market, have been found by the FDA also to contain the common cannabis chemical compound and psychoactive ingredient delta-9-tetrahydrocannabinol (THC) that is illegal in amounts of 0.3 percent or more on a dry weight basis under the Controlled Substances Act, among other unsafe ingredients.[2] As CBD products become more popular, there are increasing questions about their safety, legality, and impacts on safety-sensitive industries, including chemical distribution.

NACD Supports:

  • The FDA’s efforts to determine long-term health impacts of CBD use and to establish a regulatory framework for its safe and legal distribution; and
  • Congressional clarification for the FDA to streamline research and implement a science-based and safe framework for bringing CBD and cannabis-derived dietary supplement or food additive products to market.

Latest Action

The FDA has only regulated CBD as a pharmaceutical ingredient in the prescription drug Epidiolex, which is considered safe for its intended use alone.[3] The agency has formed a CBD Policy Working Group, with the goals of finding lawful pathways forward in the regulation of CBD as a dietary supplement and food ingredient and ensuring these products are safe for consumer use.[4]


[1] U.S. Food & Drug Administration, FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)," fda.gov, FDA, February 13, 2020, https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.

[2] Ibid.

[3] U.S. Food & Drug Administration, FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)," fda.gov, FDA, February 13, 2020, https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.

[4] Amy Abernethy, “Hemp Production and the 2018 Farm Bill,” fda.gov, FDA, July 25, 2019, https://www.fda.gov/news-events/congressional-testimony/hemp-production-and-2018-farm-bill-07252019

 

For further questions about NACD’s CBD and Cannabis-Derived Products Issue Page please contact Erin Getz, Manager of Legislative Affairs at egetz@nacd.com.